title: Immunotherapy with alloreactive T-cells?
authors.affiliation: Anthony Nolan Research Institue, London, UK.
authors.forename: Alejandro J
authors.initials: AJ
authors.lastname: Madrigal
authors.forename: Sylvie
authors.initials: S
authors.lastname: Rusakiewicz
authors.forename: Anthony I
authors.initials: AI
authors.lastname: Dodi
authors.forename: Robert
authors.initials: R
authors.lastname: Rees
mesh_terms: D000595:Amino Acid Sequence; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D015791:HLA-A3 Antigen / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D007519:Isoantigens / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism; D025941:Protein Interaction Mapping; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation*
chemical_list: D000951:Antigens, Neoplasm; D015791:HLA-A3 Antigen; D007519:Isoantigens; D010446:Peptide Fragments; D016044:Fusion Proteins, bcr-abl